

|                         |  |
|-------------------------|--|
| 1. Record Nr.           | UNINA9910865246303321  |
| Autore                  | Singh Ramanjit   |
| Titolo                  | A Guide to Hormonal Dermatology  |
| Pubbl/distr/stampa      | Singapore : , : Springer, , 2024<br>©2024  |
| ISBN                    | 981-9977-15-0  |
| Edizione                | [1st ed.]  |
| Descrizione fisica      | 1 online resource (177 pages)  |
| Altri autori (Persone)  | SharmaNidhi<br>LottiTorello<br>TrehanNaresh  |
| Lingua di pubblicazione | Inglese  |
| Formato                 | Materiale a stampa   |
| Livello bibliografico   | Monografia   |
| Nota di contenuto       | Intro -- Foreword 1 -- Foreword 2 -- Preface -- Contents -- Chapter 1: Overview of Endocrinology -- 1.1 Disorder of the Hypothalamic-Pituitary Axis -- 1.1.1 Acromegaly -- 1.1.1.1 Dermatologic Manifestations -- 1.1.2 Hypopituitarism -- 1.2 Thyroid Related Disorders -- 1.2.1 Hyperthyroidism -- 1.2.1.1 Dermatological Manifestations -- 1.2.2 Hypothyroidism -- 1.2.2.1 Dermatological Manifestations -- 1.3 Disorders of the Adrenal Gland -- 1.3.1 Cushing Syndrome -- 1.3.1.1 Dermatologic Manifestations -- 1.3.2 Primary Adrenal Insufficiency -- 1.3.2.1 Dermatologic Manifestations -- Hyperpigmentation -- 1.3.3 Other Causes of Adrenal Insufficiency and Associated Skin Manifestations -- 1.3.3.1 Skin Manifestations -- 1.3.4 Pseudohypoaldosteronism -- 1.3.4.1 Dermatological Manifestations -- 1.4 Disorder of Parathyroid Hormone -- 1.4.1 Dermatological Manifestations -- 1.5 Disorder of the Endocrine Pancreas -- 1.5.1 Diabetes Mellitus -- 1.5.1.1 Dermatologic Manifestations -- 1.5.2 Glucagonoma -- 1.5.2.1 Dermatological Manifestations -- 1.6 Disorder of Androgen Excess -- 1.6.1 Polycystic Ovarian Syndrome -- 1.6.1.1 Dermatologic Manifestations -- 1.7 Hereditary Endocrine Syndromes -- 1.7.1 Multiple Endocrine Neoplasia (MEN) Syndromes -- 1.7.1.1 MEN1 -- 1.7.1.2 MEN 2 -- 1.8 Neurofibromatosis 1 -- 1.8.1 Skin Manifestations -- 1.9 Von Hippel |

Lindau -- 1.9.1 Skin Manifestations -- 1.10 Conclusion -- References -- Chapter 2: Obesity and Skin -- 2.1 Introduction -- 2.2 Effect of Obesity on Skin Pathophysiology -- 2.3 Common Skin Changes Associated with Obesity -- 2.3.1 Acanthosis Nigricans (AN) -- 2.3.2 Keratosis Pilaris -- 2.3.3 Achrochordons -- 2.3.4 Striae Distensae (SD) -- 2.3.5 Cellulite -- 2.3.6 Plantar Hyperkeratosis -- 2.3.7 Skin Infections -- 2.4 Rare Skin Conditions Associated with Obesity -- 2.4.1 Keratosis Follicularis Squamosa (Dohi -- KFS). 2.4.2 Adiposis Dolorosa/Dercum Disease (DD) -- 2.4.3 Granular Parakeratosis -- 2.4.4 Obesity Associated Lymphedematous Mucinosis (OLAM) -- 2.5 Inflammatory Skin Diseases Associated with Obesity -- 2.5.1 Hidradenitis Suppurativa (HS) -- 2.5.2 Psoriasis -- 2.5.3 Rosacea -- 2.5.4 Hair and Scalp -- 2.5.5 Acne -- 2.5.6 Skin Malignancy -- 2.6 Conclusion -- References -- Chapter 3: Vitamin D and Skin -- 3.1 Introduction -- 3.2 Vitamin D and Its Synthesis -- 3.3 Functions of Vitamin D -- 3.4 Vitamin D Deficiency -- 3.5 Skin and Vitamin D -- 3.6 Mechanism of Action of Vitamin D -- 3.7 Atopic Dermatitis -- 3.8 Psoriasis -- 3.9 Vitiligo -- 3.10 Skin Cancers -- 3.11 Skin Pigmentation -- 3.12 Anti-aging -- 3.13 Other Skin Conditions -- 3.14 Vitamin D Dosing, Toxicity and Management -- 3.15 Conclusion -- References -- Chapter 4: Thyroid Disorders and the Skin -- 4.1 Introduction -- 4.2 Thyroid Gland -- 4.2.1 Anatomy -- 4.2.2 Embryology -- 4.2.3 Hormones -- 4.3 Thyroid Diseases -- 4.3.1 Laboratory Diagnosis -- 4.3.2 Types and Epidemiology -- 4.3.3 Hyperthyroidism -- 4.3.4 Hypothyroidism -- 4.4 Thyroid Cancer -- 4.5 Alopecia Areata -- 4.6 Chronic Idiopathic Urticaria -- 4.7 Other Thyroid Dermopathies -- 4.8 Dermatitis Herpetiformis -- 4.9 Vitiligo -- 4.10 Psoriasis -- 4.11 Miscellaneous Diseases -- 4.12 Conclusion -- References -- Chapter 5: Cutaneous Manifestations of Diabetes -- 5.1 Introduction -- 5.2 Pathogenesis -- 5.3 Cutaneous Manifestations Associated with Complications of Diabetes (Vascular and Neurological Damage) -- 5.3.1 Diabetic Dermopathy -- 5.3.2 Rubeosis Faciei -- 5.3.3 Palmar Erythema -- 5.3.4 Periungual Telangiectasias -- 5.3.5 Diabetic Foot Syndrome -- 5.3.6 Pigmented Purpuric Dermatoses -- 5.4 Cutaneous Infections in Diabetes Mellitus -- 5.4.1 Bacterial Infections -- 5.4.2 Fungal Infections. 5.5 Skin Diseases Associated with Insulin Resistance, Obesity and Metabolic Syndrome (Table 5.5) -- 5.5.1 Acanthosis Nigricans -- 5.5.2 Eruptive Xanthomas (EX) -- 5.5.3 Acrochordons -- 5.6 Skin Manifestations Associated with Diabetes -- 5.6.1 Granulomatous Disorders -- 5.6.2 Stiff Skin and Joints -- 5.6.3 Bullous Diabeticorum -- 5.6.4 Acquired Perforating Dermatitis -- 5.6.5 Other Miscellaneous Disorders -- 5.7 Cutaneous Changes Associated with Diabetes Medications (Table 5.6) -- 5.7.1 Insulin -- 5.7.2 Oral Medications -- References -- Chapter 6: Pathophysiology of PCOS -- 6.1 Introduction -- 6.2 Definition of PCOS -- 6.3 Phenotypes -- 6.4 Pathophysiology of PCOS -- 6.5 Factors Drive to PCOS (Fig. 6.2) -- 6.6 Conclusion -- References -- Chapter 7: PCOS Investigations and Clinical Implications -- 7.1 Definition of PCOS -- 7.2 Diagnostic Criteria Changing with Time -- 7.3 Diagnosis of PCOS: AACE/ACE2015 -- 7.4 What About Other Tests -- 7.5 Anti Mullerian Hormone (AMH) -- 7.6 Serum 3-Diol G: As a Marker for Idiopathic Hirsutism (IH), PCOS with Hirsutism -- 7.6.1 Alpha 3 Diol in Adult Acne -- 7.6.2 Other Features of PCOS: Not Included in the Diagnostic Criteria -- 7.6.3 Abnormal Gonadotrophin Secretion Measurements -- 7.6.4 Summary and Key Points in Diagnosis of PCOS -- References -- Chapter 8: PCOD- Management of ACNE -- 8.1 Introduction -- 8.2 Management -- 8.2.1 Non-hormonal Therapy -- 8.2.2 Oral Isotretinoin -- 8.2.3 Oral

Antibiotics -- 8.2.3.1 Hormonal Therapy -- 8.2.4 Combined Oral Contraceptives -- 8.2.5 Spironolactone -- 8.2.6 Androgen Receptor Blockers -- 8.2.6.1 Cyproterone Acetate -- 8.2.6.2 Flutamide -- 8.2.6.3 Insulin-Sensitizing Agents -- 8.2.6.4 Psychological Support -- References -- Chapter 9: Management of Pigmentation in Polycystic Ovary Syndrome -- 9.1 Introduction -- 9.2 Acanthosis Nigricans -- 9.2.1 Treatment. 9.2.1.1 General Counselling -- 9.2.1.2 Topical Medications -- 9.2.1.3 Systemic Medications -- 9.2.1.4 In-Clinic Treatment -- 9.3 Hyperprolactinemia -- 9.3.1 Treatment -- 9.3.1.1 Systemic Medications -- 9.3.1.2 Pro Tip -- 9.4 Seborrheic Dermatitis -- 9.4.1 Treatment -- 9.4.1.1 General Instruction -- 9.4.1.2 Topicals -- 9.4.1.3 Systemic Medications -- 9.4.1.4 In-Clinic Treatment -- 9.5 Post Acne PIH -- 9.5.1 Treatment -- 9.5.1.1 General Instructions -- 9.5.1.2 Topical Therapy -- 9.5.1.3 Oral Drugs -- 9.5.1.4 Pro Tip -- 9.5.1.5 In-Clinic Treatments -- 9.5.1.6 Lasers and EBD -- 9.6 DPN/Acrochordans -- 9.7 Melasma -- 9.7.1 General Instructions -- 9.7.2 Topical Treatment -- 9.7.3 In-Clinic Treatment -- 9.7.4 Lasers and EBD -- 9.8 Laser Induced Hyperpigmentation -- 9.8.1 Treatment -- 9.8.1.1 General Care -- 9.8.1.2 Topical Therapy -- 9.8.1.3 Oral Treatment -- 9.8.1.4 In-Clinic Treatment -- 9.9 Conclusion -- References -- Chapter 10: Management of Hirsutism in PCOS -- 10.1 Introduction -- 10.1.1 Causes -- 10.1.2 Evaluation -- 10.1.3 Examination -- 10.2 Treatments -- 10.2.1 General Care -- 10.2.2 Topical Treatment -- 10.2.3 Oral Treatment -- 10.2.3.1 Myoinositol -- 10.2.3.2 Oral Contraceptive Pills -- 10.3 Anti Androgens -- 10.3.1 Cyproterone Acetate [24] -- 10.3.2 Spironolactone -- 10.3.3 Flutamide/Bicalutamide [27] -- 10.3.4 Finasteride/Dutasteride -- 10.3.4.1 Glucocorticoids -- 10.3.4.2 GnRH Analogues -- 10.3.4.3 Insulin Sensitizers -- 10.3.4.4 Antifungal Agents -- 10.3.5 Alternative Therapies [31] -- 10.4 In-Clinic Treatment -- 10.4.1 Electrolysis [32] -- 10.4.2 Lasers and Lights -- 10.4.3 Mechanisms of Lasers -- 10.5 Conclusion -- References -- Chapter 11: PCOS-Management of Androgenetic Alopecia -- 11.1 Introduction -- 11.1.1 Pathogenesis -- 11.2 Investigations -- 11.3 Management -- 11.3.1 5 Alpha-Reductase Inhibitors -- 11.3.1.1 Finasteride. 11.3.1.2 Dutasteride -- 11.3.2 Cyproterone Acetate -- 11.4 Minoxidil -- 11.5 Topical Therapy -- 11.5.1 Minoxidil -- 11.6 Lasers and Light Treatments -- 11.7 Invasive Procedures -- 11.7.1 Platelet Rich Plasma Therapy -- 11.8 Microneedling -- 11.9 Hair Transplantation -- 11.10 Cosmetic Camouflage -- 11.11 Conclusion -- References -- Chapter 12: Counselling in Hair Transplant Patient -- 12.1 Introduction -- 12.2 Part 1: Basics of Hair Transplant -- 12.2.1 Section 1: Types of Hair Transplant -- 12.2.1.1 Beard, Eyebrow and Eyelash Transplant -- 12.2.2 Section 2: Procedure of Hair Transplant -- 12.2.2.1 Hairline Design Depends on -- 12.2.2.2 Theory of Safe Donor Zone in FUE [9] -- 12.2.2.3 Principles of Implantation -- 12.2.3 Implantation Techniques: (Refer Table 12.3) -- 12.2.4 Comprehensive Procedure Protocol -- 12.2.5 Advantages of CPP -- 12.2.6 Section 3: Benefits and Risks of Hair Transplant -- 12.2.6.1 Benefits of Hair Transplant -- 12.2.6.2 Possible Risks and Complications -- 12.3 Part 2: Consultation -- 12.3.1 Section 1: Purpose of Consultation -- 12.3.1.1 Importance of Consultation for Hair Transplant by a Specialist -- 12.3.1.2 Patient Selection -- 12.3.1.3 How to Manage Unhappy or Difficult Patients -- 12.3.1.4 What to Expect from a Consultation for Hair Transplant by a Specialist -- 12.3.2 Section 2: Components of Consultation -- 12.3.2.1 Hamilton-Norwood Classification -- 12.3.2.2 During the Consultation -- 12.3.2.3 During the Pre-Operative Stage --

12.3.2.4 During the Surgery (Refer Fig. 12.7) -- 12.3.2.5 In the Post-Operative Stage -- 12.3.2.6 Summary Points to Be Followed for Better Consultation -- References -- Chapter 13: Importance of Nutrition & Diet in PCOS -- 13.1 Introduction -- 13.1.1 Physiological Basis -- 13.2 Role of Gut Microbiome -- 13.2.1 Oxidative Stress and Chronic Inflammation -- 13.3 Dietary Patterns and PCOS. 13.3.1 Mediterranean Diet.

---